Murali M Chintagumpala

List of Publications by Year
in descending order

123	3,996	172457	138484
papers	citations	29 h-index	58 g-index

126	126	126	5695
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. JAMA Oncology, 2016, 2, 616.	7.1	378
2	Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. American Journal of Medical Genetics Part A, 2001, 102, 11-17.	2.4	290
3	Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. Hepatology, 2017, 65, 104-121.	7.3	192
4	Retinoblastoma: Review of Current Management. Oncologist, 2007, 12, 1237-1246.	3.7	181
5	Comparing Intelligence Quotient Change After Treatment With Proton Versus Photon Radiation Therapy for Pediatric Brain Tumors. Journal of Clinical Oncology, 2016, 34, 1043-1049.	1.6	146
6	Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma. Journal of Clinical Oncology, 2020, 38, 454-461.	1.6	143
7	Proton Beam Therapy Versus Conformal Photon Radiation Therapy for Childhood Craniopharyngioma: Multi-institutional Analysis of Outcomes, Cyst Dynamics, and Toxicity. International Journal of Radiation Oncology Biology Physics, 2014, 90, 354-361.	0.8	137
8	Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncology, The, 2020, 21, e305-e316.	10.7	115
9	Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nature Genetics, 2015, 47, 263-266.	21.4	109
10	Imaging Changes in Pediatric Intracranial Ependymoma Patients Treated With Proton Beam Radiation Therapy Compared to Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 93, 54-63.	0.8	108
11	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). Journal of Clinical Oncology, 2021, 39, 822-835.	1.6	106
12	Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534). Annals of Surgery, 2017, 266, 470-478.	4.2	99
13	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. Nature, 2020, 580, 396-401.	27.8	94
14	Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura. , 1998, 57, 293-302.		91
15	Outcomes and Acute Toxicities of Proton Therapy for Pediatric Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1143-1152.	0.8	89
16	Central Nervous System Atypical Teratoid/Rhabdoid Tumors of Infancy and Childhood. Ultrastructural Pathology, 1997, 21, 369-378.	0.9	77
17	Progressionâ€free survival of children with localized ependymoma treated with intensityâ€modulated radiation therapy or protonâ€beam radiation therapy. Cancer, 2017, 123, 2570-2578.	4.1	70
18	A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro-Oncology, 2009, 11, 33-40.	1.2	69

#	Article	IF	Citations
19	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell, 2021, 39, 1519-1530.e4.	16.8	64
20	Global Disparities in Wilms Tumor. Journal of Surgical Research, 2020, 247, 34-51.	1.6	61
21	Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients. Genome Medicine, 2014, 6, 69.	8.2	60
22	Long-term disease control and toxicity outcomes following surgery and intensity modulated radiation therapy (IMRT) in pediatric craniopharyngioma. Radiotherapy and Oncology, 2015, 114, 224-229.	0.6	57
23	Gastrointestinal autonomic nerve tumors in the pediatric population. , 1999, 85, 220-230.		55
24	Attention, processing speed, and executive functioning in pediatric brain tumor survivors treated with proton beam radiation therapy. Radiotherapy and Oncology, 2017, 124, 89-97.	0.6	53
25	Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Childrenâ€™s Oncology Group Study. Journal of Clinical Oncology, 2019, 37, 2883-2891.	1.6	51
26	Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma. Journal of Clinical Oncology, 2020, 38, 43-50.	1.6	50
27	Prospective, longitudinal comparison of neurocognitive change in pediatric brain tumor patients treated with proton radiotherapy versus surgery only. Neuro-Oncology, 2019, 21, 809-818.	1.2	46
28	Brain Tumors. Pediatric Clinics of North America, 2015, 62, 167-178.	1.8	40
29	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	1.6	40
30	Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. Acta Neuropathologica, 2020, 139, 259-271.	7.7	36
31	Cognitive Risk in Survivors of Pediatric Brain Tumors. Journal of Clinical Oncology, 2021, 39, 1718-1726.	1.6	36
32	Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clinical Cancer Research, 2021, 27, 2879-2889.	7.0	35
33	Mucoepidermoid Carcinoma in Children: A Single Institutional Experience. Pediatric Blood and Cancer, 2016, 63, 27-31.	1.5	34
34	A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study. Neuro-Oncology, 2015, 17, 1132-1138.	1.2	33
35	Vitreous Seeds in Retinoblastoma. Ophthalmology, 2017, 124, 1540-1547.	5.2	31
36	Relapsed hepatoblastoma confined to the lung is effectively treated with pulmonary metastasectomy. Journal of Pediatric Surgery, 2016, 51, 525-529.	1.6	26

#	Article	IF	Citations
37	Multimodality Treatment of Pediatric Esthesioneuroblastoma. Pediatric Blood and Cancer, 2016, 63, 465-470.	1.5	25
38	Neoplasms in neurofibromatosis 1 are related to gender but not to family history of cancer. Genetic Epidemiology, 2001, 20, 75-86.	1.3	24
39	Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients. Journal of Neuro-Oncology, 2015, 125, 307-315.	2.9	24
40	A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the childrenâ€™s oncology group. Journal of Neuro-Oncology, 2006, 77, 193-198.	2.9	23
41	Primary Malignant Rhabdoid Tumor of the Central Nervous System. Ultrastructural Pathology, 1997, 21, 361-368.	0.9	22
42	Increased risk of pseudoprogression among pediatric low-grade glioma patients treated with proton versus photon radiotherapy. Neuro-Oncology, 2019, 21, 686-695.	1.2	22
43	Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle. Journal of Physical Education and Sports Management, 2016, 2, a001057.	1.2	21
44	Metaâ€analysis of the incidence and patterns of second neoplasms after photon craniospinal irradiation in children with medulloblastoma. Pediatric Blood and Cancer, 2018, 65, e27095.	1.5	21
45	Local therapy to distant metastatic sites in stage IV rhabdomyosarcoma. Pediatric Blood and Cancer, 2018, 65, e26859.	1.5	21
46	Xenotransplantation of pediatric low grade gliomas confirms the enrichment of BRAF V600E mutation and preservation of CDKN2A deletion in a novel orthotopic xenograft mouse model of progressive pleomorphic xanthoastrocytoma. Oncotarget, 2017, 8, 87455-87471.	1.8	21
47	Germline POLE mutation in a child with hypermutated medulloblastoma and features of constitutional mismatch repair deficiency. Journal of Physical Education and Sports Management, 2019, 5, a004499.	1.2	19
48	Advances in Management of Pediatric Ependymomas. Current Oncology Reports, 2015, 17, 47.	4.0	18
49	Patterns of failure following proton beam therapy for head and neck rhabdomyosarcoma. Radiotherapy and Oncology, 2019, 134, 143-150.	0.6	18
50	Longâ€term cognitive and academic outcomes among pediatric brain tumor survivors treated with proton versus photon radiotherapy. Pediatric Blood and Cancer, 2021, 68, e29125.	1.5	18
51	Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma. Journal of Neuro-Oncology, 2021, 155, 93-100.	2.9	18
52	Renal and hepatic tumors in the neonatal period. Seminars in Fetal and Neonatal Medicine, 2012, 17, 216-221.	2.3	16
53	A patient tumor-derived orthotopic xenograft mouse model replicating the group 3 supratentorial primitive neuroectodermal tumor in children. Neuro-Oncology, 2014, 16, 787-799.	1.2	15
54	Outcomes for pediatric patients with central nervous system germ cell tumors treated with proton therapy. Clinical and Translational Radiation Oncology, 2016, 1, 9-14.	1.7	15

#	Article	IF	Citations
55	Correlation of Insurance, Race, and Ethnicity with Pathologic Risk in a Controlled Retinoblastoma Cohort. Ophthalmology, 2016, 123, 1817-1823.	5.2	15
56	Pediatric Bronchial Carcinoid Tumors: A Case Series and Review of the Literature. Journal of Pediatric Hematology/Oncology, 2019, 41, 67-70.	0.6	15
57	A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study. Neuro-Oncology, 2015, 17, 303-311.	1.2	14
58	Pulmonary Function After Treatment for Embryonal Brain Tumors on SJMB03 That Included Craniospinal Irradiation. International Journal of Radiation Oncology Biology Physics, 2015, 93, 47-53.	0.8	14
59	Technical and anatomical factors affecting intra-arterial chemotherapy fluoroscopy time and radiation dose for intraocular retinoblastoma. Journal of NeuroInterventional Surgery, 2019, 11, 1273-1276.	3.3	14
60	Primitive Myxoid Mesenchymal Tumor of Infancy Involving Chest Wall in an Infant: A Case Report and Clinicopathologic Correlation. Pediatric and Developmental Pathology, 2016, 19, 244-248.	1.0	13
61	A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. Pediatric Blood and Cancer, 2018, 65, e26832.	1.5	13
62	Patterns of failure and toxicity profile following proton beam therapy for pediatric bladder and prostate rhabdomyosarcoma. Pediatric Blood and Cancer, 2019, 66, e27952.	1.5	13
63	Neuropsychological functioning following surgery for pediatric low-grade glioma: a prospective longitudinal study. Journal of Neurosurgery: Pediatrics, 2020, 25, 251-259.	1.3	13
64	Quantifying the risk and dosimetric variables of symptomatic brainstem injury after proton beam radiation in pediatric brain tumors. Neuro-Oncology, 2022, 24, 1571-1581.	1.2	13
65	Risk-Based Therapy for Localized Osteosarcoma. Pediatric Blood and Cancer, 2016, 63, 412-417.	1.5	11
66	Adaptive functioning in pediatric brain tumor survivors: An examination of ethnicity and socioeconomic status. Pediatric Blood and Cancer, 2019, 66, e27800.	1.5	11
67	Neonatal Retinoblastoma. Clinics in Perinatology, 2021, 48, 53-70.	2.1	11
68	Spatial Dissection of Invasive Front from Tumor Mass Enables Discovery of Novel microRNA Drivers of Glioblastoma Invasion. Advanced Science, 2021, 8, e2101923.	11.2	11
69	Maternal Variation inEPHX1, a Xenobiotic Metabolism Gene, Is Associated with Childhood Medulloblastoma: An Exploratory Case-Parent Triad Study. Pediatric Hematology and Oncology, 2012, 29, 679-685.	0.8	10
70	Leukaemia & cancer in neonates. Seminars in Fetal and Neonatal Medicine, 2012, 17, 183-184.	2.3	10
71	Effect of sensorineural hearing loss on neurocognitive and adaptive functioning in survivors of pediatric embryonal brain tumor. Journal of Neuro-Oncology, 2020, 146, 147-156.	2.9	10
72	Cognitive mediators of adaptive functioning outcomes in survivors of pediatric brain tumors treated with proton radiotherapy. Pediatric Blood and Cancer, 2020, 67, e28064.	1.5	9

#	Article	IF	Citations
73	Scoliosis in Children Treated With Photon Craniospinal Irradiation for Medulloblastoma. International Journal of Radiation Oncology Biology Physics, 2021, 109, 712-717.	0.8	8
74	Early radiotherapy preserves vision in sporadic optic pathway glioma. Cancer, 2021, 127, 2358-2367.	4.1	8
75	DNA methylation of a novel PAK4 locus influences ototoxicity susceptibility following cisplatin and radiation therapy for pediatric embryonal tumors. Neuro-Oncology, 2017, 19, 1372-1379.	1.2	7
76	Pilot study of DNA methylation-derived neutrophil-to-lymphocyte ratio and survival in pediatric medulloblastoma. Cancer Epidemiology, 2019, 59, 71-74.	1.9	7
77	Pediatric high-grade glioma: a review of biology, prognosis, and treatment. Journal of Radiation Oncology, 2018, 7, 7-15.	0.7	6
78	Response criteria for intraocular retinoblastoma: RBâ€RECIST. Pediatric Blood and Cancer, 2021, 68, e28964.	1.5	6
79	Maternal and perinatal factors are associated with risk of pediatric central nervous system tumors and poorer survival after diagnosis. Scientific Reports, 2021, 11, 10410.	3.3	6
80	Neighborhood Socioeconomic Deprivation and Mortality in Children with Central Nervous System Tumors. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2278-2285.	2.5	6
81	Outcomes based on histopathologic response to preoperative chemotherapy in children with bilateral Wilms tumor: A prospective study (COG AREN0534). Cancer, 2022, 128, 2493-2503.	4.1	6
82	QOL-42. BETTER SOCIAL, COGNITIVE, AND ACADEMIC OUTCOMES AMONG PEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH PROTON VERSUS PHOTON RADIATION THERAPY. Neuro-Oncology, 2018, 20, i166-i166.	1.2	5
83	Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma. International Journal of Radiation Oncology Biology Physics, 2021, 109, 718-725.	0.8	5
84	Gadolinium is not necessary for surveillance MR imaging in children with chiasmaticâ€hypothalamic lowâ€grade glioma. Pediatric Blood and Cancer, 2021, 68, e29178.	1.5	5
85	Durable Response to Larotrectinib in a Child With Histologic Diagnosis of Recurrent Disseminated Ependymoma Discovered to Harbor an NTRK2 Fusion: The Impact of Integrated Genomic Profiling. JCO Precision Oncology, 2021, 5, 1221-1227.	3.0	5
86	Epilepsy outcome following resection of low-grade brain tumors in children. Journal of Neurosurgery: Pediatrics, 2019, 23, 726-731.	1.3	5
87	A large prospective trial of children with unilateral retinoblastoma with and without histopathologic high-risk features and the role of adjuvant chemotherapy: A Childrenâ€™s Oncology Group (COG) study.. Journal of Clinical Oncology, 2012, 30, 9515-9515.	1.6	4
88	IQ change within three years of radiation therapy in pediatric brain tumor patients treated with proton beam radiation therapy versus photon radiation therapy.. Journal of Clinical Oncology, 2013, 31, 10009-10009.	1.6	4
89	Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1 â€mutant softâ€tissue sarcoma of childhood. Journal of Pathology, 2021, 255, 52-61.	4.5	3
90	Cognitive predictors of social adjustment in pediatric brain tumor survivors treated with photon versus proton radiation therapy. Pediatric Blood and Cancer, 2022, 69, e29645.	1.5	3

#	Article	IF	Citations
91	A retrospective analysis of the patterns of failure in pediatric myxopapillary ependymoma. Journal of Radiation Oncology, 2013, 2, 21-26.	0.7	2
92	ATRT-13. LATE RECURRENCES Oâ€‹â€‹F ATYPICAL TERATOID/RHABDOID TUMOR (AT/RT) AND BENEFIT OF SALVAGE TREATMENT WITH CRANIOSPINAL IRRADIATION. Neuro-Oncology, 2019, 21, ii65-ii66.	1.2	2
93	Treatment age and neurocognitive outcomes following proton beam radiotherapy for pediatric lowâ€• and intermediateâ€grade gliomas. Pediatric Blood and Cancer, 2021, 68, e29096.	1.5	2
94	Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma. Translational Oncology, 2022, 18, 101368.	3.7	2
95	Exploratory analysis of ERCC2 DNA methylation in survival among pediatric medulloblastoma patients. Cancer Epidemiology, 2016, 44, 161-166.	1.9	1
96	Retinoblastoma in Low- and Middle-Income Countries. Pediatric Hematology and Oncology, 2019, 36, 53-54.	0.8	1
97	Reply to S.A. Milgrom et al. Journal of Clinical Oncology, 2020, 38, 2212-2213.	1.6	1
98	EXTH-07. MUTANT ISOCITRATE DEHYDROGENASE 1 (IDH1) INHIBITOR SYC-435 SYNERGISTICALLY PROLONGS ANIMAL SURVIVAL WITH STANDARD THERAPIES IN PATIENT-DERIVED IDH1 MUTANT GLIOMA XENOGRAFT MOUSE MODELS. Neuro-Oncology, 2017, 19, vi74-vi74.	1.2	0
99	PDTM-23. CD57 DEFINES A NOVEL MARKER OF GLIOBLASTOMA STEM CELLS THAT DRIVES THE INVASION OF GBM. Neuro-Oncology, 2018, 20, vi208-vi209.	1.2	0
100	RONC-09. META-ANALYSIS OF THE INCIDENCE AND PATTERNS OF SECOND NEOPLASMS AFTER PHOTON CRANIOSPINAL IRRADIATION IN CHILDREN WITH MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i176-i176.	1.2	0
101	EMBR-14. RECLASSIFICATION OF CENTRAL NERVOUS SYSTEM PRIMITIVE NEUROECTODERMAL TUMOR (CNS-PNET) INTO ENTITIES REFLECTS OUTCOME: RESULTS FROM THE PROSPECTIVE SJYC07 AND SJMB03 TRIALS. Neuro-Oncology, 2018, 20, i71-i72.	1.2	0
102	RONC-04. PROSPECTIVE, LONGITUDINAL STUDY OF NEUROCOGNITIVE CHANGE IN PEDIATRIC BRAIN TUMOR PATIENTS TREATED WITH PROTON BEAM RADIOTHERAPY VERSUS SURGERY ONLY. Neuro-Oncology, 2018, 20, i175-i175.	1.2	0
103	EMBR-13. FAVORABLE OUTCOMES IN CHILDREN WITH PINEOBLASTOMA TREATED WITH RISK-ADAPTED CRANIOSPINAL IRRADIATION AND CHEMOTHERAPY: RESULTS AND MOLECULAR ANALYSIS FROM THE SJYC07 AND SJMB03 TRIALS. Neuro-Oncology, 2018, 20, i71-i71.	1.2	0
104	TBIO-20. CLINICAL TUMOR WHOLE EXOME SEQUENCING FOR PEDIATRIC NEURO-ONCOLOGY PATIENTS â€“ RESULTS FROM THE BAYLOR ADVANCING SEQUENCING IN CHILDHOOD CANCER CARE (BASIC3) CLINICAL SEQUENCING STUDY. Neuro-Oncology, 2018, 20, i184-i184.	1.2	0
105	GENE-09. MUTATION SIGNATURE ANALYSIS IN AN ULTRAHYPERMUTATED MEDULLOBLASTOMA PREDICTS UNDERLYING GERMLINE POLYMERASE PROOFREADING DEFICIENCY IN A CHILD WITH CLINICAL FEATURES OF CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY SYNDROME. Neuro-Oncology, 2019, 21, ii82-ii83.	1.2	0
106	Multidisciplinary Subspecialty Capacity Building for Global Pediatric Oncology. JCO Global Oncology, 2020, 6, 60-60.	1.8	0
107	Ependymoma Presenting as a ÂRim-Enhancing Lesion in the Brainstem. Pediatric Neurosurgery, 2021, 56, 455-459.	0.7	0
108	Abstract 3032: A pilot study of epigenetic age acceleration and neurocognitive outcomes among survivors of pediatric medulloblastoma. , 2021, , .		0

#	Article	IF	Citations
109	Correlation of insurance status, ethnicity, and race with pathologic risk in retinoblastoma: A Children's Oncology Group (COG) study.. Journal of Clinical Oncology, 2013, 31, e17573-e17573.	1.6	0
110	Pulmonary function after treatment for embryonal brain tumors on SJMB03 that included craniospinal irradiation.. Journal of Clinical Oncology, 2013, 31, 10021-10021.	1.6	0
111	Genome-wide discovery of novel susceptibility loci for treatment-associated hypothyroidism among survivors of pediatric medulloblastoma.. Journal of Clinical Oncology, 2017, 35, 10571-10571.	1.6	0
112	IMG-03. RESPONSE ASSESSMENT IN PEDIATRIC LOW-GRADE GLIOMA: RECOMMENDATIONS FROM THE RESPONSE ASSESSMENT IN PEDIATRIC NEURO-ONCOLOGY (RAPNO) WORKING GROUP. Neuro-Oncology, 2020, 22, iii355-iii355.	1.2	0
113	IMG-07. GADOLINIUM IS NOT NECESSARY FOR SURVEILLANCE MR IMAGING IN CHILDREN WITH CHIASMATIC-HYPOTHALAMIC LOW GRADE GLIOMA. Neuro-Oncology, 2020, 22, iii356-iii356.	1.2	0
114	QOL-01. LONGITUDINAL COMPARISON OF NEUROCOGNITIVE TRAJECTORIES IN PEDIATRIC MEDULLOBLASTOMA PATIENTS TREATED WITH PROTON VERSUS PHOTON RADIOTHERAPY. Neuro-Oncology, 2020, 22, iii431-iii431.	1.2	0
115	RONC-12. TREATMENT AGE AND NEUROCOGNITIVE OUTCOMES FOLLOWING PROTON BEAM RADIOTHERAPY FOR PEDIATRIC LOW GRADE GLIOMA. Neuro-Oncology, 2020, 22, iii457-iii458.	1.2	0
116	MBCL-21. GERMLINE ELONGATOR MUTATIONS IN SONIC HEDGEHOG MEDULLOBLASTOMA. Neuro-Oncology, 2020, 22, iii392-iii393.	1.2	0
117	RONC-05. PRESERVING VISION IN OPTIC PATHWAY GLIOMA AMONG PATIENTS WITHOUT NEUROFIBROMATOSIS TYPE 1. Neuro-Oncology, 2020, 22, iii457-iii457.	1.2	0
118	PATH-29. HIGH FREQUENCY OF CLINICALLY-RELEVANT TUMOR VARIANTS DETECTED BY MOLECULAR TESTING OF HIGH-RISK PEDIATRIC CNS TUMORS â€“ PRELIMINARY FINDINGS FROM THE TEXAS KidsCanSeq STUDY. Neuro-Oncology, 2020, 22, iii430-iii430.	1.2	0
119	ETMR-06. DISSECTING THE MOLECULAR AND DEVELOPMENTAL BASIS OF PINEOBLASTOMA THROUGH GENOMICS. Neuro-Oncology, 2020, 22, iii323-iii324.	1.2	0
120	EPEN-46. DNA METHYLATION LANDSCAPE OF RECURRENT PEDIATRIC EPENDYMOMA IDENTIFIES KEY DRIVER EVENTS. Neuro-Oncology, 2020, 22, iii317-iii317.	1.2	0
121	LGG-04. Clinical and molecular characterization of metastatic pediatric low grade gliomas. Neuro-Oncology, 2022, 24, i87-i87.	1.2	0
122	MODL-29. Molecular Landscape of a comprehensive panel of pediatric brain cancer Patient-derived orthotopic xenograft (PDOX) models inform unique targets for drug responsiveness. Neuro-Oncology, 2022, 24, i175-i175.	1.2	0
123	A Prospective Evaluation of Fatigue in Pediatric Brain Tumor Patients Treated With Radiation Therapy. , 0, , 275275302110560.		0